T. Rowe Price Associates
CNCE

T. Rowe Price Associates’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

T. Rowe Price Associates’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-39,705
Closed -$745K – 2548
2015
Q3 		$745K Buy
+39,705
New +$675K ﹤0.01% 1798

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

T. Rowe Price Associates's CNCE Position: Q4 2015 in Review

T. Rowe Price Associates sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2015, closing a stake of 39,705 shares — an estimated $745K sold.

T. Rowe Price Associates first reported a position in CNCE in Q3 2015 and held it in 1 quarter. The position peaked at $745K in Q3 2015. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2015.

  • T. Rowe Price Associates reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • T. Rowe Price Associates sold 39,705 Concert Pharmaceuticals, Inc. shares in Q4 2015, an estimated $745K.
  • T. Rowe Price Associates first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • T. Rowe Price Associates's Concert Pharmaceuticals, Inc. position peaked at $745K in Q3 2015.
  • 93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2015.

Based on T. Rowe Price Associates's 13F filing for Q4 2015, filed 16 Feb 2016.